2017 American Transplant Congress Archives

T Cell Responses to Viral Peptide Stimulation Predict Influenza Vaccine-Induced Seroconversion in Pediatric Solid Organ Transplant Recipients.

E. Mayer,¹ M. Altrich,² C. Cordes,² S. Fausett,² J. Tepp,³ R. Albrecht,³ A. Fernandez-Sesma,³ B. Herold,¹ I. Ramos,³ R. Madan.¹
T-Cell Aging Parameters in the Lymph Node and Peripheral Blood Are Strongly Associated but Terminally Differentiated T Cells Are Mainly Located within the Circulation.

B. Dedeoglu,¹ A. de Weerd,¹ L. Huang,¹ A. Langerak,² M. Klepper,¹ W. Verschoor,¹ D. Reijerkerk,¹ C. Baan,¹ N. Litjens,¹ M. Betjes.¹
T_FR:T_FH Cell Ratio Correlates with Anti-Donor Germinal Center Reactivity and Donor-Specific Antibody Formation Following Transplantation.

G. La Muraglia II, M. Ford, I. Badell.
TACI Polymorphisms Associated with De Novo Alloantibodies in Humans and Allograft Rejection in Mice.

J. Platt,¹ E. Farkash,² A. Lefferts,¹ M. Samaniego,³ M. Cascalho.¹
Tacrolimus and Mycophenolate Exposure and Subclinical Tubulo-Interstitial Inflammation in Low Immunological Risk Renal Transplants.

I. Torres,¹ A. Reisaeter,² F. Moreso,¹ A. Asberg,² M. Perello,¹ C. Dörje,² J. Sellares,¹ K. Midtved,² H. Holdaas,² D. Seron.¹
Tacrolimus and Mycophenolic Acid Have a Limited Inhibitory Effect on Monocyte Signaling Pathway Phosphorylation, Function and Differentiation.

N. Kannegieter,¹ D. Hesselink,¹ M. Dieterich,¹ R. Kraaijeveld,¹ A. Rowshani,¹ P. Leenen,² C. Baan.¹
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.

M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² G. Mourad,¹ M. Le Quintrec.^1,3
Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients.

L. Qu, Z. Xie, H. Huang, H. Jiang, J. Chen, H. Jiang, H. Jiang, J. Chen, J. Chen, J. Chen.
Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.

S. Seibert,¹ D. Schladt,² B. Wu,³ W. Guan,³ C. Dorr,^2,7 D. Berglund,¹ R. Remmel,⁴ A. Matas,⁵ R. Mannon,⁶ A. Israni,^2,7 W. Oetting,¹ P. Jacobson,¹ For the DeKAF Genomics Investigators.
Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients.

A. Leino,¹ T. Kaiser,¹ Y. Zou,² E. King,² A. Vinks,² W. Jiang,⁴ U. Christians,³ E. Woodle,¹ R. Alloway.¹
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.

S.-Y. Kim,¹ J. Oh,² S. Yun,² I.-J. Jang,² S.-I. Min,¹ W. Cho,¹ S. Cho,¹ S. Ahn,¹ S.-K. Min,¹ J. Ha.¹
Tacrolimus Suppresses Calcineurin Activity and Ca2+ Influx Age-Specifically.

F. Krenzien,^1,2 M. Quante,¹ H. Uehara,¹ R. Abdi,¹ H. Cetina Biefer,¹ M. Schmelzle,² J. Pratschke,² A. Elkhal,¹ S. Tullius.¹
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.

S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.

D. Taber, Z. Su, A. Posadas, M. Gebregziabher, L. Egede, D. Dubay, J. McGillicuddy, C. Bratton, S. Nadig, K. Chavin, P. Baliga.
Tangible Benefits in Caregiving Burden Among Spouses/Partners of Transplant Patients: Adding “Donor Benefit” to Live Donor Risk Assessment.

S. Rasmussen, L. Duquette, M. Henderson, D. Segev.
Targeting JAK-STAT Pathways with Tofacitinib Provides a Novel Approach for Conditioning in Allogeneic BMT Recipients.

H. Xu, A. Merchak, M. Xu, C. Mort, T. Dowling, L. Kahn, M. Binion, A. Chhabra, Y. Wen, Y. Huang, S. Ildstad.
TB Chemoprophylaxis Post Transplantation in West London.

Y. Al-Mula Abed,¹ R. Charif,² O. Kon,³ D. Taube.²
Technical Characteristics, Optimization and Outcomes of Ultrasound-Guided Biopsy Performed on Kidney Transplant Patients.

J. Juega, M. Perez, L. Cañas, M. Troya, I. Bancu, J. Bonet, R. Lauzurica.
Technical Refinement to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation: Simplified One-Orifice Venoplasty.

J. Kim, D. Choi.
Technically Successful Miniaturization of Blood Hemofilters for an Artificial Kidney via Bioengineering Techniques.

R. Forbes,¹ C. Kensinger,¹ S. Karp,¹ J. Groszek,¹ A. Buck,² D. Colvin,² S. Roy,³ W. Fissell.¹
Technique and Result of Anastomosing Right Hepatic Vein to Inferior Vena Cava with a Separate Cavotomy Inferior to Right Hepatic Vein Orfice.

R. Rai, E. Trivedi, I. Shaikh, S. Nagral, N. Doctor.
Telemedicine Utilization After Kidney Transplantation Was Not Associated with Decreased Early Hospital Readmission Rate.

N. Elfadawy, E. Sanchez, K. Woodside, J. Augustine, D. Hricik, N. Sarabu.
Temporal Trends and Variation in BMI Thresholds for Living Donation Across the US.

A. Naik,¹ D. Cibrik,¹ A. Sakhuja,² K. Lentine.³
Tenofovir Use Is Not Associated with Reduced Bone Density or Fractures in Liver Transplant Recipients.

N. Lim, C. Engler, J. Lake.
Testing the Efficacy of Contrast Enhanced Ultrasound in Detecting Transplant Rejection Using a Murine Model of Heart Transplantation.

K. Fisher,¹ M. Uehara,² S. Ohori,² C. Meral,¹ S. Giannini,³ T. Ichimura,² N. Smith,⁴ F. Jolesz,¹ I. Guleria,² Y. Zhang,¹ P. White,¹ N. McDannold,¹ K. Hoffmeister,³ M. Givertz,⁵ R. Abdi.²
TGF-β1 Induces Transplant Kidney Interstitial Fibrosis Through Endothelial-to-Mesenchymal Transition via TGF-β/Smad and Akt/mTOR/p70S6K Pathways.

Z. Wang, Z. Han, J. Tao, R. Tan, M. Gu.
The 'W' Technique: A Safe and Reproducible Technique for Hepatic Arterial Reconstruction in Living Donor Liver Transplantation.

V. Kumaran, V. Varma, S. Kapoor, B. Nath, A. Chauhan, S. Sable, K. Yadav, S. Kumar, S. Sharma.
The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database.

Q. Liu,¹ A. Smith,¹ J. Park,² M. Oguntimein,³ S. Dutcher,³ G. Bello,¹ M. Helmuth,¹ M. Turenne,¹ R. Balkrishnan,⁴ M. Fava,¹ P. Sharma,² C. Beil,¹ A. Leichtman,¹ J. Zee.¹
The American Transplant Congress Effect on Kidney Discard Rates in the United States.

D. Abdelwahab,¹ G. Wei,² I. Hall.²
The Association of Donor Vasoactive Drugs with Pancreas Transplant Graft Survival.

I. Shapey,¹ P. Yianoullou,² A. Summers,² T. Augustine,² M. Rutter,¹ D. van Dellen.²
The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing.

K. Flabouris,^1,2 S. Chadban,^1,3,4 M. Ladhani,^1,3,5 M. Cervelli,⁶ P. Clayton.^1,2,6
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.

A. Hart,^1,2 S. Gustafson,² A. Wey,² N. Hadley,² A. Israni.²
The Beneficial Effect of Janus Kinase 3 Inhibitor on Transplanted Islet via Protection from Oxidative Stress-Induced β Cell Death.

S.-J. Kang,^1,2,3,4 H. Chung,^1,2,3,4 S. Lee,^1,2,3,4 J.-S. Shin,^1,3,5 H.-J. Kim,^1,2,3,4 J.-M. Kim,^1,3,5 B.-H. Min,^1,3,5 S. Choi,^1,2,3,4 C.-G. Park.^1,2,3,4,5
The Beneficial Effects of mTOR Inhibitors on Liver Resident Natural Killer Cells.

J. Saparbay, Y. Tanaka, T. Yano, H. Ohdan.
The Benefits of Pancreas After Kidney (PAK) Transplantation.

M. Curry,¹ J. Odorico,² J. Fridell.³
The Clinical and Economic Burden of Pneumonia in Canadian Solid Organ Transplant Recipients.

N. Law,¹ B. Hamandi,² A. Alghamdi,¹ E. Papadimitropoulos,² S. Husain.¹
The Clinical Significance of Red Cell Distribution Width (RDW) in Kidney Transplant Recipients.

S. Park,¹ J. Ha,¹ Y. Kim,¹ H. Lee,¹ Y. Kim,¹ C. Lim,¹ I. Jung,¹ D.-J. Han,² S.-K. Park,² Y. Kim,² J. Lee.¹
The Combined Effects of Induction Regimens and Antiviral Prophylaxis on the Risk of CMV Infection in Different Serostatus Subgroups After Liver Transplantation.

C. Low,² S. Hosseini-Moghaddam,^1,2 C. Rotstein,² E. Renner,² A. Humar,² D. Kumar,² S. Husain.²
The Cumulative United States Experience with Transplants (Txs) from Living Donors (LDs): 140,156 LD Txs in 28 Years.

R. Gruessner,¹ M. Laftavi,¹ V. Whittaker,¹ O. Pankwycz,² Z. Acun,¹ A. Gruessner.¹
The Degree of NK Cell Activation Determines the Ability of Donor-Specific Antibodies to Mediate Acute vs. Chronic Rejection of Kidney Allografts.

T. Yagisawa,^1,2 T. Tanaka,¹ N. Dvorina,¹ A. Valujskikh,¹ W. Baldwin 3rd,¹ R. Fairchild.¹
The Delivery of Stem Cell Therapy to Extended Criteria Donor Human Livers Using Normothermic Machine Perfusion.

R. Laing,¹ S. Stubblefield,³ B. Ricky,¹ S. Barnaby,² M. Alfaifi,¹ A. Ting,³ D. Mirza,² P. Newsome,¹ H. Mergental,² S. Afford.¹
The Effect of BMI on Renal Transplant Outcomes.

E. Giorgakis,¹ K. Reddy,¹ A. Singer,¹ H. Khamash,² R. Heilman.²
The Effect of Histological Isolated Endarteritis and Solid Endoarteritis Combined with CD20 Positive B Cell Infiltration Appeared in Acute Cellular Rejection on Kidney Allograft Survival.

R. Wang, Y. Jiang, J. Wu, W. Peng, H. Huang, J. Chen.
The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response.

N. Murakami,¹ T. Win,¹ T. Borges,¹ C. Lian,¹ G. Murphy,¹ E. Bueno,¹ R. Clark,¹ T. Strom,² B. Pomahac,¹ L. Riella.¹
The Effect of Semimature Dendritic Cell on Transplantation Tolerance of Hepatocytes Differentiated from Mouse Embryonic Stem Cells.

A. Hu, C. Zhang, W. Liao, X. Zhu, X. He.
The Effect of the Procurement Surgeon on Transplanted Abdominal Organ Outcomes: An OPTN/SRTR Analysis to Evaluate Regional Organ Procurement Collaboration.

O. Serrano,¹ D. Vock,² R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ E. Finger.¹
The Effect of Transplant Center Volume on Survival Outcomes for Patients Listed for Simultaneous Liver and Kidney Transplantation.

R. Modi,¹ D. Tumin,² E. Beal,^3,4 D. Hayes Jr.,^4,5 J. Hanje,^4,6 A. Michaels,^4,6 K. Washburn,^3,4 L. Conteh,^4,6 S. Black,^3,4 K. Mumtaz.^4,6
The Effects of Aspirin on Major Adverse Cardiac Events and Kidney Allograft Outcomes: A Meta-Analysis.

W. Cheungpasitporn, C. Thongprayoon, D. Mitema, M. Mao, W. Kittanamongkolchai, M. Gonzalez-Suarez, S. Erickson.
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.

S. Rhazouani,^1,4 S. Anwar,² D. Brennan,¹ K. Lentine,³ K. Venkatachalam,¹ A. Malone,¹ T. Alhamad.¹
The Effiency and Safety of Chemotherapy for Urothelial Carcinoma in Post-Kidney Transplanted Patients.

Y. Zhu, J. Lin.
The Evolution of Hepatitis B Surface Antibody (Anti-HBs) Titer of the Kidney Transplant Recipients: A 5-Year Experience Guideline for the Optimal Maintaining Immunization.

W. Chancharoenthana, A. Leelahavanichkul, S. Wattanatorn, Y. Avihingsanon, K. Praditpornsilpa, N. Townamchai.
The Feared Five Fungal Infections in Kidney Transplant Recipients: 20-Year Experience at a Midwestern Center.

S. Parajuli, A. Wick, S. Pandeya, B. Astor, J. Smith, A. Djamali, D. Mandelbrot.
The Forgotten Element of KAS: A2 to B Transplantation Reduces Waiting Time for Blood Group B Patients by 20%.

A. Gilbert, S. Radomski, A. Langeberg, B. Diedrich, S. Rosen-Bronson, D. Li, M. Awwad, M. Grafals, J. Moore, J. Verbesey, P. Abrams, S. Ghasemian, M. Cooper.
The Glasgow Prognostic Score and Its Variants Predict Mortality in Living Donor but Not in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Double-Center Validation Study.

A. Kaltenborn,¹ J. Gwiasda,¹ N. Heits,² F. Braun,² H. Schrem.¹
The Gut Microbiota Regulates Murine Cardiac Transplant Outcome.

Y. Xiong, C. Brinkman, L. Hittle, W. Fricke, E. Mongodin, J. Bromberg.
The IL6/Th17 Pathway May Play Different Roles in Cell-Mediated and Antibody-Mediated Alloimmune Injury in Renal Allografts.

D. Dobi,¹ Q. Tang,² S. Chandran,³ F. Vincenti,³ Z. Laszik.¹
The Immunophenotype of Peritubular Capillaritis in Renal Transplant Biopsies.

T. Chen,¹ L. Rasch,¹ T. Al Johani,² H. McPhail,¹ M. Willicombe,³ A. McLean,³ J. Galliford,³ T. Cook,¹ C. Roufosse.¹
The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes.

C. Reuter,¹ R.-A. Lee,¹ R. Watkins,³ S. Lieber,² K. Szempruch,¹ D. Gerber,⁴ G. DeCherney,² A. Barritt IV.²
The Impact of Belatacept on Anti-HLA Antibodies of Highly Sensitized Kidney Transplant Recipients.

R. Parsons, H. Decker, T. Pearson, C. Larsen, R. Bray, H. Gebel.
The Impact of Delayed Graft Function on Long Term Graft Survival Adjusted for Donor Kidney Quality Assessed by the KDPI.

L. Lehner, F. Halleck, D. Khadzhynov, E. Schrezenmeier, M. Dürr, K. Budde, O. Staeck.
The Impact of Early Clinical and Subclinical T Cell Rejection After Kidney Transplantation.

W. Hoffman, P. Sood, R. Mehta, A. Cherukuri, C. Wu, C. Puttarajappa, N. Shah, P. Randhawa, A. Tevar, S. Hariharan.
The Impact of Elevated Doppler Resistive Indices in Renal Transplant Recipients with Delayed Graft Function.

D. Mikhail,¹ E. Chan,² G. Aboalsamh,³ S. Cruise,⁴ S. Aquil,³ M. Mohamed,³ A. Sener,^1,3 P. Luke.^1,3
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.

J. Husson, R. Adekunle, B. Ravichandran, P. Mathur, S. Jonchhe, K. Stafford.
The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys.

T. Butler, N. Hayde.
The Impact of Insurance Status on Waiting List and Post-Lung Transplant Survival in Patients with Cystic Fibrosis.

C. Lehr,¹ M. Skeans,² E. Dasenbrook,¹ M. Valapour.^1,2
The Impact of Marginal Factors on the Postoperative Kidney Function of Complex Living Donors for Kidney Transplantation.

T. Hiramitsu, K. Futamura, M. Okada, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.
The Impact of Scleroderma Diagnosis on Lung Transplant Outcomes: A Single Center's Experience.

H. Memon, A. Frost, E. Graviss, D. Nguyen, A. Goodarzi, N. Sinha.
The Impact of Social Support on Kidney Transplant Listing Decisions: Results from a Discrete Choice Experiment.

K. Ladin,^1,2 J. Emerson,² Z. Butt, E. Gordon, D. Hanto, T. Lavelle.²
The Impact of Tacrolimus and MPA Derivative Immunosuppression on Acheived GFR in Recipients without Rejection: A Comparison of GFR of Living Donor Recipient Pairs at Six Months Post-Transplant.

D. Keith.
The Impact of the Donor Risk Index on Tumor Free Survival in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma.

D. Moonka,¹ S. Nagai,² A. Harper, R. Salgia.¹
The Impact of the Kidney Allocation System on Outcomes for Kidneys with KDPI > 85%.

A. Perry,¹ J. Sageshima,¹ C. Santhanakrishnan,¹ J. McVicar,¹ C. Troppmann,¹ A. De Mattos,² J. Woloszyn,¹ R. Perez.¹
The Impact of the New Kidney Allocation System on Length of Dialysis Prior to Transplantation.

T. Melanson,¹ M. Basu,¹ L. Plantinga,¹ S. Pastan,¹ S. Mohan,² R. Patzer.¹
The Impact of the New Kidney Allocation System on Living Donor Kidney Transplantation(LDTX) Among Patients in the Lowest Quintile of Expected Post-Transplant Survival (EPTS).

C. Rose, J. Gill, J. Lesage, Y. Joffres, J. Gill.
The Impact of Tracheal Epithelial Cells Apoptosis on the Biological Behavior of Bone Marrow Mesenchymal Stem Cells (BMSCs) in OB.

X. Zhang,¹ T. Xia,² C. Wang,² K. Jiang,² J. Wang,² J. Nie.²
The Implication of the Dominant Side Split Renal Function by Diethylenetriamine Penta-Acetic Acid (DTPA) in Live Kidney Donor.

H. Lee,¹ Y. Yoon,¹ S. Kang,¹ K. Huh,² M. Kim,² S. Kim,² Y. Kim,² W. Han.¹
The Incidence and Outcomes of Fever of Unknown Origin After Pancreas Transplantation.

R. Klasek,¹ S. Kuten,¹ S. Patel,^1,3 D. Nguyen,¹ E. Graviss,¹ A. Gaber,¹ R. Knight.¹
The Incidence, Mortality and Prediction Model for Fractures After Kidney Transplantation in the United States.

X. Liu, S. Bae, M. McAdams DeMarco, D. Segev.
The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis.

D. Axelrod,¹ K. Lentine,² M. Schnitzler,² H. Xiao,² X. Lou,³ B. Orandi,³ J. Garonzik Wang,³ A. Massie,³ D. Segev.³
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.

A. Assounga,^1,2 S. Omarjee.¹
The Innate Immune-System May Play an Enhanced Role in Acute Cellular Rejection in Patients on Belatacept-Based Immunosuppression.

D. Dobi,¹ Q. Tang,² S. Chandran,³ F. Vincenti,³ Z. Laszik.¹
The Intragraft Vascularized Bone Marrow Component and Recipient T Regulatory Cells Facilitate Tolerance Induction After Post Transplant High Dose Cyclophosphamide Treatment in VCA.

G. Furtmüller, B. Oh, M. Fryer, S. Ganguly, V. Malek, X. Zhou, J. Dodd-o, G. Raimondi, D. Cooney, C. Brayton, W. Lee, L. Luznik, G. Brandacher.
The miRNome of EBV+ PTLD is Distinct from EBV+ Infectious Mononucleosis.

Y. Balachandran,¹ V. Kaul,¹ E. Maloney,¹ A. Harris-Arnold,¹ K. Weinberg,² S. Boyd,² D. Bernstein,² C. Esquivel,¹ O. Martinez,¹ S. Krams.¹
The Molecular Phenotypes of Rejection in Kidney Transplant Biopsies.

P. Halloran, J. Reeve, INTERCOMEX Study Group.
The mTOR Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury.

C. Yang, C. Zhang, R. Rong, T. Zhu.
The Natural History of Kidney Rejection: How Do Molecular Disease States Change Over Time in Patients with Repeat Indication Biopsies?

J. Reeve, P. Halloran.
The New Kidney Allocation System in France Meets it's Targets: Improving Age and HLA DR-QD Matching for Young Adults.

C. Jacquelinet, B. Audry, F. Bayer, M. Macher.
The New Kidney Allocation System: The Effect on Elderly Transplantation in the US. Review of UNOS Database.

V. Whittaker, M. Laftavi, Z. Acun, R. Gruessner, A. Gruessner.
The Novel Establishment of Neuroma in Continuity Animal Model Based on Buccal Nerve in Rats.

Y.-H. Hsieh,^1,2 C.-J. Wen,^1,3 C.-H. Lin,^1,2,3,4 F.-C. Wei,^1,2,3 Y.-C. Pei.^3,5
The Objective Liver Frailty Index Significantly Improves the Clinician “Eyeball Test” to Predict Mortality in Liver Transplant Candidates.

J. Lai, K. Covinsky, C. McCulloch, S. Feng.
The Outcome of 0 Mismatch Kidney in Pediatric Population with High Immunologic. The Impact of Induction Therapy. An Analysis of UNOS Database.

V. Whittaker, M. Laftavi, Z. Acun, R. Gruessner, A. Gruessner.
The Outcome of Kidney Grafts from Living Donors with Pyelo-Ureteric Junction Dysfunction.

C. Gledhill-Flynn, H. Ali, A. Ahmed.
The Paradox in Pancreas After Kidney Transplantation (PAK): Better Results but Fewer Transplants Despite an Increase in High-Risk Patients.

O. Pankewycz,¹ A. Gruessner,² M. Laftavi,² V. Whittaker,² V. Aggarwal,¹ R. Gruessner.²
The Performance of Four Tools for the Prediction of Potential for Organ Donation After Cardiac Death in Neurocritical Patients: A Prospective, Multicenter, Observational Study.

Z. Guo,¹ G. Xu,¹ P. Schroder,² M. Manyalich,³ X. He,¹ G. Chen.¹
The Phenotypic and Functional Characteristics of a Novel CD11b⁺CD11c⁺F4/80⁺ Monocytic Myeloid-Derived Suppressor Cell Subset.

B. Jiang,^1,2 I. Aljabban,¹ C. Yang,¹ D. Ndishabandi,¹ R. White,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.

K. Minami,^1,3 H. Uehara,¹ A. Elkhal,¹ S. Bae,³ J. Reder,² B. Houser,² P. Kang,³ S. Tullius.¹
The Relationship Between Frailty and Decreased Physical Performance with Death on the Kidney Transplant Waiting List.

E. Lorenz, F. Cosio, S. Bernard, S. Bogard, B. Bjerke, E. Geissler, S. Hanna, W. Kremers, M. Stegall, A. Cheville, N. LeBrasseur.
The Role of Anti-Neu5Gc IgM in Xenograft Antibody Mediated Rejection.

W. Hassanein,¹ G. Braileanu,¹ L. Burdorf,¹ W. Sun,¹ B. French,¹ C. Laird,¹ S. Sendil,¹ C. Ahn,³ D. Ayares,² R. Pierson III,¹ A. Azimzadeh.¹
The Role of Natural Killer Cells in Recognition and Killing of Stem Cells and Stem Cell-Derived Hepatoblasts.

T. Cisneros, D. Dillard, M. Castro, J. Arredondo-Guerrero, S. Krams, C. Esquivel, O. Martinez.
The Role of Toll-Like Receptor 4 in Islet Transplantation and a Novel Method of Protection Using Chemical Surface Modification.

C. Chang,¹ G. Yoshimatsu,² B. Akinbobuyi,⁴ M. Lawrence,² R. Kane,¹ B. Naziruddin.³
The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction.

S. Chong,¹ R. Fernando,² M. Harber,¹ C. Magee.¹
The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis.

Z. Guo, J. Gu, X. He, G. Chen.
The Search for a Polyomavirus BK Nephropathy (BKPyVN)-Specific Transcriptomic Signature.

L. Pan,¹ G. Zeng,² Z. Lyu,³ Y. Huang,² P. Randhawa.²
The TAKE-IT Intervention Improves Medication Adherence in Adolescent Kidney Transplant Recipients.

B. Foster,¹ A. Pai,² S. Furth,³ TAKE-IT Investigators.
The Transcription Factor Batf and IRF1 Controls IL-10/IL-27 Expression in Dendritic Cells and Transplant Tolerance Induction.

G. Gu, H. Hang, Q. Xia.
The Treatment of the Graft and the Recipient with α-Lipoic Acid Improves the Delay Graft Function Severity in the Human Kidney Transplant.

G. Weber,¹ N. Ambrosi,² F. Caro,² S. Beltramino,¹ A. Fernández,¹ I. Cabrera,¹ G. Hilchenbach,¹ D. Fernandez,¹ C. Incardona,³ E. Chuluyan,² D. Casadei.¹
The Treg/Th17 Axis: A Dynamic Balance Regulated by Stromal Laminins.

T. Simon, J. Bromberg.
The Ultimate Calculated Panel Reactive Antibody Value Predicts Mortality After Heart Transplantation.

E. Kransdorf,¹ M. Kittleson,¹ J. Patel,¹ M. Pando,² L. Czer,¹ J. Kobashigawa.¹
The Unfunded OPTN/UNOS Mandate of Living Kidney Donor Follow-Up: Fewer Than 50% of Centers in Compliance.

M. Henderson, A. Thomas, A. Massie, X. Luo, A. Shaffer, C. Holscher, D. Segev.
The Use of a Furosemide Stress Test (FST) for Assessment of Discarded Deceased Donor Kidneys in an Ex-Vivo Normothermic Perfusion Model.

I. Palma, Y. Smolin, S. Kabagambe, A. Perry, I. Palma, J. Sageshima, R. Perez.
The Use of an Haemoglobin Based Oxygen Carrier in a Human Liver Model of Normothermic Machine Perfusion.

Y. Boteon,¹ R. Laing,¹ R. Bogal,¹ D. Neil,² A. Smith,² B. Stephenson,² A. Schlegel,² S. Hübscher,² D. Mirza,² S. Afford,¹ H. Mergental.²
The Use of Kidneys from Deceased Donors Over 80 Years in Kidney Transplantation.

M. Pérez-Sáez,¹ E. Arcos,² J. Comas,² J. Pascual.¹
The Use of Very High KDPI Kidneys in Elderly Kidney Transplant Recipients – Discarded in the U.S. but Successfully Transplanted in Europe.

F. Halleck, D. Khadzhynov, G. Rehse, L. Lehner, E. Schrezenmeier, M. Dürr, K. Budde, O. Staeck.
The Value of Protocol Biopsy at Third Month After Kidney Transplant: A Single-Center Cohort Analysis.

R. Rosado-Canto, C. Barrientos-Aguilar, I. Parra-Avila, L. Marino, M. Arvizu-Hernandez, N. Uribe-Uribe, L. Morales-Buenrostro.
Third Liver Transplantation, Outcomes, and the Impact of Previous Graft Survival.

M. Barry,¹ M. Gupta,² D. Goldberg,³ M. Levine,² D. Simpson,² K. Olthoff,² A. Shaked,² P. Abt.²
This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.

C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'Brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² D. Taber.²
Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis.

A. Umber, M. Killackey, A. Paramesh, B. Alper, F. Teran, A. Baudy, Y. Liu, J. Buell, R. Zhang.
Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.

S. Patel,¹ J. Benken,¹ S. Akkina,³ P. West-Thielke,² J. Thielke,¹ M. Campara,¹ J. Oberholzer,² E. Benedetti.²
Thrombalexin and Mirococept Synergistically Reduce IBMIR in a Porcine to Rhesus Xenoislet Model.

M. Manook,^1,2 J. Kwun,¹ J. Yoon,¹ K. Samy,¹ A. MacDonald,¹ H. Xu,¹ R. Smith,³ A. Dorling,³ A. Kirk,¹ N. Mamode,² S. Knechtle.¹
Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation.

M. Manook,^1,2 J. Kwun,¹ J. Yoon,¹ K. Samy,¹ A. MacDonlad,¹ H. Xu,¹ R. Smith,³ S. Sacks,³ A. Dorling,³ N. Mamode,² S. Knechtle.¹
TIE'ing Statins to Microvascular Stability and Endothelial Cell Immunogenicity.

C. Ghosh,¹ A. Mak,¹ M. McGourty,¹ S. Parikh,² X. Chen,² S. Goldberg,¹ J. Wedel,¹ D. Briscoe.¹
TIM-3 – CEACAM1 Checkpoint Regulation of T-Cell Activation and Hepatocellular Function in Liver Transplantation.

K. Nakamura,¹ S. Kageyama,¹ M. Kujawski,³ R. Sosa,² E. Reed,² A. Zarrinpar,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
TIM-4 Identifies Pro-Inflammatory B Effector Cells That Are Potent Drivers of Alloimmunity and Allograft Rejection Through Expression of Both IFN-γ and IL-17.

Q. Ding, K. Mohib, D. Rothstein.
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?

O. Witkowsky, J. Teuteberg, C. Sciortino, M. Shullo.
Time to Kidney Transplantation Following Live Donor Candidate Referral.

K. Kumar, J. Tonascia, A. Muzaale, A. Poon, T. Purnell, J. Garonzik-Wang, E. King, M. Bowring, A. Massie, D. Segev.
Timing of HLA Testing as a Means of Reducing Cost and Increasing Efficiency of Living Kidney Donation.

E. Venniro, J. Taylor.
Timing of Mesenchymal Stem Cell Infusions Affects Rejection Free and Overall Islet Allograft Survival.

N. Kenyon,¹ M. Willman,¹ D. Han,¹ A. Rabassa,¹ W. Diaz,¹ R. Leeman,¹ K. McHenry,² D. Salomon,³ A. Bartholomew,⁴ N. Kenyon,¹ D. Berman.¹
Timing, Frequency, and Precipitating Factors of Early Readmission After Heart Transplant.

J. Van Liew, L. Potter, N. Uriel, L. Lourenco.
TIMP-3 Plays a Key Regulatory Role in the Cleavage of E-Cadherin and Has an Essential Protective Function in Hepatic IRI.

T. Fujii, S. Duarte, R. Busuttil, A. Coito.
Tissue Transcriptional Profile of Portal Inflammation with Interface Activity in Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests Closely Resembles T Cell Mediated Rejection (TCMR).

A. Sanchez-Fueyo, S. Feng, A. Demetris, J. Bucuvalas, J. Lozano, J. Magee, K. Spain, S. Kanaparthi, iWITH Investigators.
Titers of Blood Group B Patients Using Non-A1 Reagent/Donor Cells for the Purpose of ABO Incompatible Kidney Transplantation.

D. King, M. Aguilucho, M. Marchioni, B. Figueiredo, I. Okere, P. Rao.
TNF[part]-I After Kidney Transplantation.

B. Muth, B. Astor, D. Mandelbrot.
To Accept or Not Accept, That Is the Question: Donor Heart Selection Process and Outcome of Discarded Organs Transplanted in Another Center.

A. Aliabadi-Zuckermann,¹ J. Goekler,¹ A. Kaider,² J. Riebandt,¹ R. Moayedifar,¹ E. Osorio,¹ T. Haberl,¹ G. Laufer,¹ J. Smits,³ A. Zuckermann.¹
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).

B.-H. Shin,¹ M. Everly,² J. Choi,¹ S. Ge,¹ A. Petrosyan,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹
Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting.

G. Raimondi,¹ X. Calderon-Colon,² J. Budihardjo,¹ A. Mirdad,¹ M. Iglesias-Lozano,¹ J. Walch,¹ W. Lee,¹ G. Brandacher,¹ J. Patrone.²
Tolerant Pediatric Liver Transplant (LT) Recipients (TOL) from WISP-R (NCT00320606) Split into Two Phenotypically Distinct Groups by PD1 Expression on CD4+ T Cells at Baseline, Prior to Immunosuppression Withdrawal (ISW).

B. Burrell,¹ S. Feng,² N. Bridges,³ U. Ekong,⁴ S. Kanaparthi,¹ A. Kirk,⁵ A. Long,¹ K. Spain,⁶ L. Stempora,⁵ L. Turka,¹ N. Tchao.¹
Tolerogenic Potential, Migratory Pathways, Engraftment and Long-Term Survival of Human Hematopoietic Chimeric Cells – A Novel Strategy to Induce Tolerance in Transplantation.

M. Siemionow, E. Bryndza Tfaily, E. Szilagyi, J. Cwykiel, S. Uygur, M. Czerwinski.
Toll-Like Receptor 4-Dependent CCAAT-Enhancer-Binding Protein Homologous Protein Activation Induces Hepatocellular Cell Death in Liver Ischemia and Reperfusion Injury.

H. Zhou,¹ Z. Rao,² H. Wang,¹ X. Wang,¹ L. Lu.¹
Total Pancreatectomy and Islet Autotransplantation into the Liver of a Patient with Previous Hepatitis C Infection.

A. Rajab,¹ J. Buss,¹ P. Hart,² D. Conwell,² S. Black,¹ K. Washburn.¹
Total Pancreatectomy with Islet Autotransplantation Improves Quality of Life Allowing for the Resolution of the Intractable Pain with Good Glucose Control in Properly Selected Patients with Chronic Pancreatitis.

A. Kotukhov,¹ J. Solomina,¹ E. Konsur,¹ K. Cieply,¹ L. Basto,¹ L.-J. Wang,¹ K. Golab,¹ M. Tibudan,¹ A. Gelrud,² C. Thomas,² J. Matthews,¹ P. Witkowski.¹
Tracking the In Vitro Phenotype and Proliferative Capacity of CD57+ CD4 T Cells.

J. Espinosa,¹ J. Lockley,¹ F. Shaw,¹ R. Osborne,¹ M. Joshi,¹ T. Woody,¹ M. Ellis,¹ B. Hollister,¹ J. Cheeseman,¹ R. Townsend,² A. Kirk.¹
Trafficking of Donor Leukocytes and Recipient Cells Cross-Dressed with Donor MHC Molecules After Transplantation of Cardiac Allografts in Monkeys.

J. Marino, K. Robinson, J. Paster, I. Hanekamp, J. Madsen, G. Benichou.
Training for Transplant: Frailty Assessment and Optimization in Kidney Transplant Candidates.

M. Mrdutt, D. Doherty, S. Tanner, J. Lappin.
Transcatheter Relief of Symptomatic Hepatic Venous Outflow Obstruction Following Pediatric Liver Transplantation.

B. Goldstein, G. Tiao, M. Alonso, N. Johnson, J. Heubi, K. Averin, J. Bucuvalas.
Transcript Changes Associated with Graft Rejection Are Not Specific for Rejection Because They Are Shared with Tissue Responses to Wounding.

P. Halloran, K. Famulski, INTERCOMEX Study Group.
Transcriptome Analysis of CD4-Lymphocyte Specifically Deleted of IKKbeta or NEMO in an Experimental Model of Rapid Progressive Glomerulonephritis (RPGN).

F. Thaiss,¹ J. Huang,² M. Chen,¹ H. Paust,¹ G. Zahner,¹ M. Alawi,² R. Geffers,³ L. Guo.¹
Transcriptomic Analysis Revealed a Fibrotic Role of Epithelial Cells Originated from the Recipient in Kidney Transplant.

W. Zhang,¹ Z. Yi,¹ E. Stahl,² M. Menon,¹ K. Keung,³ K. Hao,² P. O'Connell,³ B. Murphy.¹
Transient High Dose Tacrolimus Allows Tolerance of a Vascularized Composite Allograft Tolerance Across a Full MHC Mismatch.

A. Leto Barone, H. Wang, E. Swanson, K. Kolegraff, J. Lopez, G. Furtmüller, B. Oh, S. Alfadil, S. Mermulla, J. Sacks, S. Bonawitz, G. Raimondi, J. Shores, D. Cooney, W. Lee, G. Brandacher.
Transplant Center Knowledge and Planned Practice of HIV Positive-to-Positive Transplants.

S. Rasmussen, M. Bowring, A. Shaffer, C. Durand, D. Segev.
Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients.

D. Taber, M. Gebregziabher, L. Egede, P. Baliga.
Transplant Economics Post Implementation of the Affordable Care Act and the Budget Control Act Sequestration Adjustment on Medicare Reimbursement.

E. Zavala,¹ J. Rogers,² R. Howey,³ S. Karp.¹
Transplant Professionals' Attitudes and Approaches to the Living Kidney Donor-Recipient Relationship: Interview Study.

A. Ralph,^1,2,3 P. Butow,^3,4,5 J. Craig,^1,2 J. Chapman,⁸ J. Gill,⁶ J. Kanellis,⁷ A. Tong.^1,2
Transplant Readiness Assessment Clinic: A New Approach to Kidney Waitlist Management in the KAS Era.

X. Cheng,¹ J. Lee,² Z. Tulu,² J. Tan.²
Transplant without Borders – A New Project for Decentralization of Transplant Centers in Brazil.

M. Perosa, J. Branez, L. Mota, B. Zeballos, H. Noujaim, M. Paredes, T. Miranda, G. Martinho, T. Genzini.
Transplantation of Chimeric Cells of Myoblast and Mesenchymal Stem Cell Origin for Restoration of Muscle Function.

M. Siemionow, E. Szilagyi, J. Cwykiel, A. Domaszewska-Szostek, A. Heydemann, J. Garcia-Martinez.
Transplantation of Hepatitis C Kidneys to Hepatitis C Recipients Confers Significantly Shorter Waiting Times in the Era of the New Kidney Allocation System.

B. Concepcion, A. Langone, B. Edmundson, J. Johnson, A. Rajput, T. Johnson, D. Rybacki, D. Hale, R. Forbes.
Transplantation of Organs from Donors with Hepatitis C: The Potential to Substantially Increase Transplant Activity.

P. Trotter,^1,2 M. Robb,² I. Ushiro-Lumb,² J. Powell,³ C. Watson,¹ J. Bradley,¹ J. Neuberger.^2,4
Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER] Trial.

D. Goldberg, E. Blumberg, R. Reddy, S. Nazarian, V. Van Deerlin, J. Trofe-Clarke, M. Levine, D. Sawinski, R. Bloom, P. Abt, P. Reese.
Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis.

B. Kiberd,¹ K. Tennankore,¹ K. Doucette.²
Treating Ischemically Damaged Porcine Kidneys with Mesenchymal Stromal Cells During Normothermic Machine Perfusion.

M. Pool,¹ J. Sierra Parraga,² M. Roemeling-van Rhijn,³ M. Reinders,⁴ M. Hoogduijn,² R. Ploeg,^1,5 H. Leuvenink,¹ C. Moers.
Treating Refractory Liver Allograft Rejection with Photopheresis.

I. Lopez Plaza,¹ A. Eisenbrey,¹ M. Raoufi,¹ A. Yoshida,² D. Moonka.²
Treatment and Outcomes of Simultaneous Acute Rejection and Polyomavirus Allograft Nephropathy.

T. Sparkes, S. Hammad, C. Drachenberg, A. Haririan.
Treatment of Post-Transplant Nephrotic Syndrome with Adrenocorticotropic (ACTH) Gel.

A. Khalil,² A. Karabala,¹ A. Sharfuddin,² M. Grafals.¹
Trends in Infection Among Kidney Transplant Recipients, 1999-2013.

S. Bae, C. Durand, L. Kucirka, S. DiBrito, R. Avery, J. Garonzik Wang, D. Segev.
Trends in Liver Transplantation Among Older Adults with ESLD.

C. Haugen,¹ Q. Huang,² M. Pozo,¹ M. McAdams-DeMarco,² D. Segev.^1,2
Trends in Long-Term Outcomes of Kidney Transplantation in Australia and New Zealand.

W. Lim,¹ W.-C. Yeung,² S. Campbell,³ S. Chadban,⁴ P. Clayton,⁵ C. Hawley,³ D. Johnson,³ S. McDonald,⁵ E. Pascoe,⁶ G. Wong,⁷ S. Badve.²
Trends in the Number and Medical Urgency of Adult Heart Transplant Candidates Listed as Status 1A from 2006-2015.

W. Parker,¹ M. Churpek,¹ S. Fedson,² E. Garrity.¹
Triptolide Alleviating Acute Antibody Mediated Rejection by Inhibition of B Cell Activation in Presensitized Recipients.

D. Zhao,¹ S. Li,¹ T. Liao,¹ Y. Wei,² X. Hua,¹ F. Han,¹ Z. Luo,¹ X. Liu,¹ Q. Sun.
TRPV4 Channels Mediate Pulmonary Edema and Inflammation During Ischemia-Reperfusion Injury.

E. Charles, Y. Zhao, K. Hong, C. Marziano, J. Mehaffey, I. Kron, S. Sonkusare, V. Laubach, A. Sharma.
Truth in Pathology: Autopsy Findings in Lungs Declined for Transplantation.

A. Friedman, J. Lewis, H. Irving, K. Delli Carpini.
Twelve Hour Ex Vivo Normothermic Perfusion for the Assessment of High-Risk Discarded Deceased Donor Kidneys.

I. Palma, I. Palma, Y. Smolin, S. Kabagambe, A. Perry, J. Sageshima, R. Perez.
Twenty Year Trends in Outcomes and Costs Following Kidney Transplantation.

A. Ojo,¹ N. Agashivala,² L. Gache,³ W. Irish.³
Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates.

K. Huh,¹ W. Sommer,¹ K. Robinson,¹ X. Wu,¹ J. Paster,¹ I. Hanekamp,¹ A. Dehnadi,¹ T. Kawai,^1,2 R. Smith,³ R. Colvin,^1,3 G. Benichou,¹ J. Madsen.^1,4
Two Promoter Polymorphisms in the Genes Encoding for Complement Regulating Proteins CD46 and CD59 in Kidney Donors Are Associated with Biopsy Proven Acute Rejection.

L. Michielsen,¹ A. van Zuilen,¹ T. Kardol-Hoefnagel,² M. Verhaar,¹ H. Otten.²
Type 1 Diabetic Patients Have Better Endothelial Function After Simultaneous Pancreas-Kidney Transplantation Than After Kidney Transplantation with Continued Insulin Therapy.

A. Kolonko,² A. Kowalik,¹ J. Ziaja,¹ D. Kaminska,³ A. Owczarek,⁴ A. Kujawa-Szewieczek,² M. Kusztal,³ J. Badura,¹ D. Bozek-Pajak,¹ A. Zakrzewska,⁵ P. Choreza,⁴ R. Krol,¹ S. Chlopicki,⁵ M. Klinger,³ A. Wiecek,² J. Chudek,⁶ L. Cierpka.¹
Type of Surgical Procedures and Clinical Significance of Calcineurin Inhibitor Temporary Discontinuation Regarding LT Recipients Undergoing Major Elective Surgery.

C. Cho, J. Lee, K. Kim, S. Kim, J. Lee, K. Lee, J.-M. Kim, G.-S. Choi, C. Kwon, J.-W. Joh.
Type-1 Interferon Impairs the Immunoregulatory Activity of IL-10: A Mechanism in the Abrogation of Transplant Tolerance.

M. Iglesias, A. Arun, B. Lam, W. Lee, G. Raimondi, G. Brandacher.